OGOmid Ghamarnejad

Omid Ghamarnejad

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Omid Ghamarnejad has a total of 81 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Same Patient, Same Space, Divergent Needs: Revealing Gaps and Design Opportunities in Surgeon–Anesthesiologist Collaboration

    by Hamraz Javaheri, Omid Ghamarnejad, Konrad Schwarzkopf, Jakob Karolus, Gregor A Stavrou, Paul Lukowicz

  • Open Access

    Assessing the Feasibility of Using Apple Vision Pro While Performing Medical Precision Tasks: Controlled User Study

    by Hamraz Javaheri, Vitor Fortes Rey, Paul Lukowicz, Gregor A Stavrou, Jakob Karolus, Omid Ghamarnejad

    Background: The emergence of next-generation video-see-through head-mounted displays, such as the Apple Vision Pro (AVP), has generated considerable interest in the medical field. While preliminary studies highlight AVP’s potential, no controlled study has rigorously assessed its usability for precision-based medical tasks requiring fine motor control and real-world perception. Objective: This study aims to evaluate the feasibility of using AVP while performing real-world medical precision tasks. Methods: To assess AVP’s feasibility, we conducted a controlled user study with 20 health care professionals, who performed 3 different suturing techniques across 3 intervention conditions. Participants completed the same tasks using AVP, the Microsoft HoloLens 2 (MHL2), and a baseline (without a head-mounted display). A within-subject design was used, ensuring that each participant experienced all intervention groups. We used a mixed methods research approach, incorporating both quantitative metrics, including task completion time, suturing performance, system usability score, cognitive load, virtual reality sickness, and presence score, as well as qualitative insights gathered through interviews. Results: Participants took significantly longer to complete the entire task using AVP (570.0, SD 192.0 s) compared with MHL2 (456.0, SD 120.0 s; P<.001) and baseline (472.0, SD 143.0 s; P<.001). The analysis on participants’ average suture performance revealed no significant differences across interventions (P=.76). The total raw NASA Task Load Index score among participants was significantly higher for AVP (43.9, SD 15.9) compared with MHL2 (21.5, SD 13.8; P<.001) and baseline (19.1, SD 15.1; P<.001). The analysis of the presence questionnaire demonstrated a significantly higher presence score for MHL2 (115.0, SD 11.4) compared with AVP (93.7, SD 12.7; P<.001). The overall virtual reality sickness questionnaire score was significantly higher for AVP (66.9, SD 19.8) compared with MHL2 (41.1, SD 9.32; P<.001). Moreover, the calculated system usability score for MHL2 (72.7, SD 8.54) was significantly higher compared with AVP (50.3, SD 14.4; P<.001). Conclusions: In conclusion, AVP has potential for non–time-sensitive medical applications or those that emphasize digital elements over real-world interaction. Its current usability limitations, particularly increased cognitive load and prolonged task execution times, suggest that further optimizations are necessary before widespread clinical adoption is feasible.


  • Open Access

    LLMs Enable Context-Aware Augmented Reality in Surgical Navigation

    by Hamraz Javaheri, Omid Ghamarnejad, Paul Lukowicz, Gregor Alexander Stavrou, Jakob Karolus


  • Open Access

    Transforming liver surgery: the shift from traditional resections to minimally invasive and parenchymal-sparing techniques

    by Omid Ghamarnejad, Rizky Widyaningsih, Gregor Alexander Stavrou

    Transforming liver surgery: the shift from traditional resections to minimally invasive and parenchymal-sparing techniques


  • Open Access

    ARAS: LLM-Supported Augmented Reality Assistance System for Pancreatic Surgery

    by Hamraz Javaheri, Omid Ghamarnejad, Paul Lukowicz, Gregor Alexander Stavrou, Jakob Karolus

    The integration of Augmented Reality (AR) technology into surgical procedures offers significant potential to enhance clinical outcomes. Despite numerous lab-proven prototypes, deploying these systems in actual clinical settings demands specialized design and rigorous clinical evaluation to meet the high standards of complex medical fields. Our research highlights the intricate requirements emerging from clinical environments, particularly operating theaters. To address these challenges, we introduce ARAS, an operational AR assistance system for open pancreatic surgery. Through a user-centric design methodology, ARAS was iteratively developed and refined, ensuring its practical applicability and effectiveness in real-world surgical settings during clinical trials. ARAS encompasses two different modes designed for preoperative and intraoperative sessions. Preoperative mode enables surgeons to visualize patient data and perform resection on the patient's 3D reconstructed vessels and tumors, helping surgeons during surgical planning. Intraoperative mode allows in-situ and precise visualization of these reconstructed 3D models during the surgical procedure and supports surgeons in decision-making. ARAS also includes a novel interaction design for surgical AR systems. It uses LLMs to enable context-aware, intuitive, and natural communication between surgeons and the AR system. This demo showcases the capabilities of ARAS, emphasizing its potential to transform surgical practices through advanced AR and LLM-supported interactions.


  • Open Access

    Promising Results of Associating Liver Partition and Portal Vein Ligation for Staged Hepatectomy for Perihilar Cholangiocarcinoma in a Systematic Review and Single-Arm Meta-Analysis

    by Mohammad Golriz, Ali Ramouz, Ahmed Hammad, Ehsan Aminizadeh, Nastaran Sabetkish, Elias Khajeh, Omid Ghamarnejad, Carlos Carvalho, Hugo Rio-Tinto, De-Hua Chang, et al.

    Background: ALPPS popularity is increasing among surgeons worldwide and its indications are expanding to cure patients with primarily unresectable liver tumors. Few reports recommended limitations or even contraindications of ALPPS in perihilar cholangiocarcinoma (phCC). Here, we discuss the results of ALPPS in patients with phCC in a systematic review as well as a pooled data analysis. Methods: MEDLINE and Web of Science databases were systematically searched for relevant literature up to December 2023. All studies reporting ALPPS in the management of phCC were included. A single-arm meta-analysis of proportions was carried out to estimate the overall rate of outcomes. Results: After obtaining 207 articles from the primary search, data of 18 studies containing 112 phCC patients were included in our systematic review. Rates of major morbidity and mortality were calculated to be 43% and 22%, respectively. The meta-analysis revealed a PHLF rate of 23%. One-year disease-free survival was 65% and one-year overall survival was 69%. Conclusions: ALPPS provides a good chance of cure for patients with phCC in comparison to alternative treatment options, but at the expense of debatable morbidity and mortality. With refinement of the surgical technique and better perioperative patient management, the results of ALPPS in patients with phCC were improved.


  • Open Access

    Correction: Oweira et al. Kynurenine Is the Main Metabolite of Tryptophan Degradation by Tryptophan 2,3-Dioxygenase in HepaRG Tumor Cells. J. Clin. Med. 2022, 11, 4794

    by Hani Oweira, Imad Lahdou, Stefan Mehrle, Elias Khajeh, Rajan Nikbakhsh, Omid Ghamarnejad, Peter Terness, Christoph Reißfelder, Mahmoud Sadeghi, Ali Ramouz

    There was an error in the original publication


  • Open Access

    Declined Organs for Liver Transplantation: A Right Decision or a Missed Opportunity for Patients with Hepatocellular Carcinoma?

    by Vladimir J. Lozanovski, Said Adigozalov, Elias Khajeh, Omid Ghamarnejad, Ehsan Aminizadeh, Christina Schleicher, Thilo Hackert, Beat Peter Müller-Stich, Uta Merle, Susanne Picardi, et al.

    Background: Liver transplantation is the only promising treatment for end-stage liver disease and patients with hepatocellular carcinoma. However, too many organs are rejected for transplantation. Methods: We analyzed the factors involved in organ allocation in our transplant center and reviewed all livers that were declined for transplantation. Reasons for declining organs for transplantation were categorized as major extended donor criteria (maEDC), size mismatch and vascular problems, medical reasons and risk of disease transmission, and other reasons. The fate of the declined organs was analyzed. Results: 1086 declined organs were offered 1200 times. A total of 31% of the livers were declined because of maEDC, 35.5% because of size mismatch and vascular problems, 15.8% because of medical reasons and risk of disease transmission, and 20.7% because of other reasons. A total of 40% of the declined organs were allocated and transplanted. A total of 50% of the organs were completely discarded, and significantly more of these grafts had maEDC than grafts that were eventually allocated (37.5% vs. 17.7%, p < 0.001). Conclusion: Most organs were declined because of poor organ quality. Donor-recipient matching at time of allocation and organ preservation must be improved by allocating maEDC grafts using individualized algorithms that avoid high-risk donor-recipient combinations and unnecessary organ declination.


  • Open Access

    Kynurenine Is the Main Metabolite of Tryptophan Degradation by Tryptophan 2,3-Dioxygenase in HepaRG Tumor Cells

    by Hani Oweira, Imad Lahdou, Stefan Mehrle, Elias Khajeh, Rajan Nikbakhsh, Omid Ghamarnejad, Peter Terness, Christoph Reißfelder, Mahmoud Sadeghi, Ali Ramouz

    There are two main enzymes that convert tryptophan (Trp) to kynurenine (Kyn): tryptophan-2,3-dioxygenase (TDO) and indoleamine 2,3-dioxygenase (IDO). Kyn accumulation can promote immunosuppression in certain cancers. In this study, we investigated Trp degradation to Kyn by IDO and TDO in primary human hepatocytes (PHH) and tumoral HepaRG cells. To quantify Trp-degradation and Kyn-accumulation, using reversed-phase high-pressure liquid chromatography, the levels of Trp and Kyn were determined in the culture media of PHH and HepaRG cells. The role of IDO in Trp metabolism was investigated by activating IDO with IFN-γ and inhibiting IDO with 1-methyl-tryptophan (1-DL-MT). The role of TDO was investigated using one of two TDO inhibitors: 680C91 or LM10. Real-time PCR was used to measure TDO and IDO expression. Trp was degraded in both PHH and HepaRG cells, but degradation was higher in PHH cells. However, Kyn accumulation was higher in the supernatants of HepaRG cells. Stimulating IDO with IFN-γ did not significantly affect Trp degradation and Kyn accumulation, even though it strongly upregulated IDO expression. Inhibiting IDO with 1-DL-MT also had no effect on Trp degradation. In contrast, inhibiting TDO with 680C91 or LM10 significantly reduced Trp degradation. The expression of TDO but not of IDO correlated positively with Kyn accumulation in the HepaRG cell culture media. Furthermore, TDO degraded L-Trp but not D-Trp in HepaRG cells. Kyn is the main metabolite of Trp degradation by TDO in HepaRG cells. The accumulation of Kyn in HepaRG cells could be a key mechanism for tumor immune resistance. Two TDO inhibitors, 680C91 and LM10, could be useful in immunotherapy for liver cancers.